MAP2K7 and cancer: A clinical trial in advanced cancer patients with the CI-1040 (an oral MEK inhibitor) shows the usual toxicities of CI-1040 were mild or moderate, like diarrhea, nausea, asthenia, and vomiting [65].Compared with solo therapy, combination therapy with MEK inhibitors seems to be more promising.